Patent intelligence · US
US 12257288
Methods of inducing immune tolerance to clotting factors
Methods of inducing immune tolerance to clotting factors
Patent details — US 12257288
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 25, 2025
- Expiration
- Mar 20, 2045
- Applicant
- BIOVERATIV THERAPEUTICS INC.
- Claims
- 19
- CPC classes
- A61K, A61K38/37, A61K38/4846, A61P
Quick answer
US 12257288 (Methods of inducing immune tolerance to clotting factors) is held by BIOVERATIV THERAPEUTICS INC.. Status: granted. Granted Mar 25, 2025. Expires Mar 20, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BIOVERATIV THERAPEUTICS INC.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K38/37, A61K38/4846, A61P, A61P7/04
More from BIOVERATIV THERAPEUTICS INC.
Related pharmaceutical patents in our USPTO index.
-
US 12403164
Lentiviral vector formulations
granted -
US 12403183
Factor VIII polypeptide formulations
granted -
US 12391750
Anti-C1S antibodies and methods of use thereof
granted -
US 12371747
Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy
granted -
US 12364774
Nucleic acid molecules and uses thereof for non-viral gene therapy
granted -
US 12268688
Compositions and methods of use for modified release minoxidil
granted -
US 12240917
Anti-complement C1s antibodies and uses thereof
granted
Frequently asked questions
What is US patent 12257288?
US 12257288 (Methods of inducing immune tolerance to clotting factors) is held by BIOVERATIV THERAPEUTICS INC.. Status: granted. Granted Mar 25, 2025. Expires Mar 20, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12257288?
BIOVERATIV THERAPEUTICS INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 140 pharmaceutical patents for this assignee.
When does US 12257288 expire?
Our index shows an expiration date of Mar 20, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.